Cellectis gene/cell therapy, genomics news
In February, Cellectis' Cellartis AB subsidiary announced that is participating in the EU's Innovative Medicines Initiative (IMI) Mechanism based Improved Prediction of Drug-Induced Liver Injury (MIP-DILI) project. The consortium has a €32 million ($42.4 million) five-year budget to develop preclinical liver test systems that are "mechanism-based and of physiological, pharmacological and pathological relevance" to drug-induced liver injury (DILI) in humans. Cellartis will generate human induced pluripotent stem (iPS) cell lines from DILI and non-DILI sensitive individuals. These lines will be characterized, expanded and banked, and will ultimately be used to generate hepatocytes for the project.
The consortium includes universities, and biotechs and pharmas, including Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.), CXR Biosciences Ltd. (Dundee, U.K.), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.), the Orion Pharma R&D subsidiary of Orion Corp. (HSE:ORNAV; HSE:ORNBV, Espoo, Finland), Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) and Solvo Biotechnology (Budaors, Hungary). ...